Before and after Gleevec, Brian Druker

Interviewee: Brian Druker. Brian Druker talks about the drug he developed as a turning point in the war on cancer. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Before and after Gleevecâ„¢)

One of my very favorite articles was written by The Chicago Tribune and the opening quote was, "In the war on cancer there will be before Gleevecâ„¢ and after Gleevecâ„¢." And although it may be a bit presumptuous, I certainly hope that that's the way Gleevecâ„¢ is remembered. Because my own view is that if you can do it with chronic myeloid leukemia, meaning if you can understand what drives the growth of cancer, target that with a specific treatment that's effective and non-toxic, you can do that with every single cancer. And what's unique about chronic myeloid leukemia is not the cancer, but our understanding of it. We understand what drives the growth and we can treat it early in the course of the disease.

chronic myeloid leukemia,brian druker,gleevec,location applications,cancer drug,chicago tribune,dnai,target,interviewee,cml,leukemia,turning point,genes,medicine

Related Content

15056. Approval for Gleevec in record time, Brian Druker

Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.

  • ID: 15056
  • Source: DNAi

15082. Shutting down cancer with Gleevec, Brian Druker

Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.

  • ID: 15082
  • Source: DNAi

15054. Restoring hope with Gleevec, Brian Druker

Brian Druker talks about how Gleevec has restored patients' hope for the future.

  • ID: 15054
  • Source: DNAi

15055. Using DNA science to control CML, Brian Druker

Brian Druker talks about how the drug he designed targets the molecular cause of CML.

  • ID: 15055
  • Source: DNAi

15042. The first day of clinical trials for Gleevec, Bud and Yvonne

Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.

  • ID: 15042
  • Source: DNAi

15041. Getting the diagnosis of chronic myeloid leukemia, Bud

Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.

  • ID: 15041
  • Source: DNAi

1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1

Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.

  • ID: 1013
  • Source: IC

15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration

View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.

  • ID: 15525
  • Source: DNAi

16109. Sense of urgency, Brian Druker

Brian Druker talks about sense of urgency.

  • ID: 16109
  • Source: DNAi

1014. Diagnosis, Targeted therapies: Targeting activators, Sawyer 2

Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.

  • ID: 1014
  • Source: IC